96 Tests PN: B113389
Components:
45x Ab-conjugated beads (S5P9- human sEpCAM Ab-bead). PN: B113389A. One vial containing 100 µL of anti-human sEpCAM conjugated to AimPlex Bead S5P9.
25x Biotin-detection (human sEpCAM Biotin-dAb). PN: B113389B. One vial containing 100 µL of biotinylated anti-human sEpCAM.
Lyophilized Standard Mix-Human Group 9 Panel B, 9-Plex. PN: HG9009B. One vial containing lyophilized recombinant human sCEACAM-1, sALCAM, sSLAMF4, sHVEM, sB7-DC, sB7-H1, sEpCAM, sBLAME and sEPOR. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.
Application: Optimal antibody pair and antigen standard for assaying human Human EpCAM/MK-1/TROP1/sCD326. Can be multiplexed with other analytes in Human Group 9. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.
Storage: 2-8 C in the dark.
Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.
For Research Use Only. Not for use in diagnostic procedures.
Assay Specifications:
Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate
Sensitivity (LOD): < 10 pg/mL
Quantitation range:
LLOQ: < 20 pg/mL
ULOQ: > 10,000 pg/mL
Standard dose recovery: 70-130%
Intra-assay CV: < 10%
Inter-assay CV: < 20%
Cross-reactivity of analytes in Human Group 9: Negligible
Sample volume: 15 µL/test
Description:
Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein mediating Ca2+-independent homotypic cell-cell adhesion in epithelia. EpCAM is also involved in cell signaling, migration, proliferation, and differentiation. Since EpCAM is expressed exclusively in epithelia and epithelial-derived neoplasms, EpCAM can be used as diagnostic marker for various cancers. It appears to play a role in tumorigenesis and metastasis of carcinomas, so it can also act as a potential prognostic marker and as a potential target for immunotherapeutic strategies. EpCAM was initially described as a dominant surface antigen on human colon carcinoma. EpCAM has many aliases the most notable of which include TACSTD1 (tumor-associated calcium signal transducer 1), CD326 and the 17-1A antigen. EpCAM expression is not limited to human colon carcinomas; in fact, EpCAM is expressed in a variety of human epithelial tissues, carcinomas, and progenitor and stem cells. However, EpCAM is not found in non-epithelial cells or cancers of non-epithelial origin. EpCAM is expressed on the basolateral membrane of all simple (especially glandular), pseudo-stratified, and transitional epithelia. In contrast, normal squamous stratified epithelia are negative for EpCAM. The level of expression may differ significantly between the individual tissue types. In the gastrointestinal tract, the gastric epithelium expresses very low levels of EpCAM. Expression levels are substantially higher in small intestine, and in colon EpCAM is probably expressed at the highest levels among all epithelial cell types.
References:
Litvinov, Sergey; et al. (1994). "Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule". The Journal of Cell Biology 125 (2): 437–46. doi:10.1083/jcb.125.2.437. PMC 2120036. PMID 8163559.
Maetzel, Dorothea; et al. (2009). "Nuclear signalling by tumour-associated antigen EpCAM". Nature Cell Biology 11 (2): 162–71. doi:10.1038/ncb1824. PMID 19136966.
Osta, WA; et al. (2004). "EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy". Cancer Res 64 (16): 5818–24. doi:10.1158/0008-5472.CAN-04-0754. PMID 15313925.
Litvinov, Sergey; et al. (1996). "Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation". Am J Pathol 148 (3): 865–75. PMC 1861708. PMID 8774141.